GRTS News and Press, Gritstone Oncology Inc. From 05/12/23

2023-05-12 12:06:28 ET Gritstone bio ( NASDAQ: GRTS ) stock fell ~10% on Friday after Q1 revenue missed estimates. Net loss widened to -$33.98M, compared to -$28.92M in Q1 2022. Total revenues fell -66% Y/Y to $2.44M. Collaboration and license revenues decline...

2023-05-11 22:42:14 ET Gritstone bio, Inc. (GRTS) Q1 2023 Earnings Conference Call May 11, 2023 4:30 AM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co founder, President and Chief Executive Offi...

2023-05-11 16:08:35 ET Gritstone bio press release ( NASDAQ: GRTS ): Q1 GAAP EPS of -$0.30 beats by $0.04 . Revenue of $2.44M (-66.1% Y/Y) misses by $0.73M . For further details see: Gritstone bio GAAP EPS of -$0.30 beats by $0.04, revenue of $2.44M misse...

-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE...

EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update follow...

2023-04-23 04:25:21 ET Summary Results from the phase 2/3 GRANITE study using GRANITE immunotherapy to treat patients with metastatic microsatellite stable colorectal cancer are expected in Q4 of 2023. It is said that the global colorectal cancer market is expected to grow from $1...

2023-04-21 17:40:45 ET Gainers: Starbucks Corporation ( SBUX ) +6% . Caesars Entertainment ( CZR ) +5% . Gritstone bio ( GRTS ) +4% . JFrog ( FROG ) +3% . UP Fintech Holding  ( TIGR ) +3% . Losers: Presto Automation ...

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated (“vaccine-naïve”) South African subjects -- -- Updated CORAL-BOOS...

-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations associated with conversion of “cold” to “hot” tumors and molecular res...

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectiou...